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Application of stem cell biology to breast can-
cer research has been limited by the lack of
simple methods for identification and isolation
of normal and malignant stem cells. Utilizing
in vitro and in vivo experimental systems, we
show that normal and cancer human mammary
epithelial cells with increased aldehyde dehy-
drogenase activity (ALDH) have stem/progeni-
tor properties. These cells contain the subpop-
ulation of normal breast epithelium with the
broadest lineage differentiation potential and
greatest growth capacity in a xenotransplant
model. In breast carcinomas, high ALDH activ-
ity identifies the tumorigenic cell fraction, capa-
ble of self-renewal and of generating tumors
that recapitulate the heterogeneity of the paren-
tal tumor. In a series of 577 breast carcinomas,
expression of ALDH1 detected by immuno-
staining correlated with poor prognosis. These
findings offer an important new tool for the
study of normal andmalignant breast stem cells
and facilitate the clinical application of stem cell
concepts.
INTRODUCTION
Although the concept that cancers arise from ‘‘stem’’ or
‘‘germ cells’’ was first proposed almost 150 years ago, it
is only recently that advances in stem cell biology gener-
ated the experimental framework necessary to test this
hypothesis (Reya et al., 2001; Sell, 2004). According to
the cancer stem cell model, tumors originate in either tis-
sue stem cells or progenitor cells through deregulation of
the normally tightly regulated process of self-renewal
(Molofsky et al., 2004; Passegue et al., 2003). Self-renewal
is the process by which stem cells generate progenyCell Sidentical to themselves. Stem cells also differentiate to
generate multipotent progenitors, which in turn give rise
to committed progenitors and differentiated cells. Cancer
stem cells share these properties with their normal coun-
terparts: they have self-renewal capacity, driving tumori-
genicity, recurrence, and metastasis, and they have the
capacity to differentiate, albeit aberrantly, giving rise to
a heterogeneous population of cancer cells. The differen-
tiated cells constitute the bulk of the tumor, but they are
not tumorigenic due to their lack of self renewal capacity
and limited proliferation potential. Experimental evidence
supporting the cancer stem cell hypothesis was first gen-
erated in 1997 by Dick’s group, who demonstrated that
human leukemias are driven by a small population of
leukemic stem cells capable of transferring the disease
to NOD/scid mice (Bonnet and Dick, 1997). This concept
was extended to solid tumors by Clarke and Wicha.
They demonstrated that human breast cancers contain
a cell population with stem cell properties bearing the
surface markers CD44+/CD24–/lin– (Al-Hajj et al., 2003).
Subsequently, cancer stem cells have been identified
and prospectively isolated from a variety of malignancies,
including brain cancers, prostate cancer, melanoma, mul-
tiple myeloma, colon, pancreatic, and head and neck can-
cers (Collins et al., 2005; Fang et al., 2005; Li et al., 2007;
Matsui et al., 2004; O’Brien et al., 2006; Prince et al., 2007;
Ricci-Vitiani et al., 2006; Singh et al., 2004a, 2004b).
It is likely that cancer stem cells have a phenotype de-
fined by the cell of origin (stem cells or early progenitor
cells) and by the oncogenic events that contributed to
transformation. Recent studies have provided evidence
that supports this concept (Jamieson et al., 2004; Kelly
and Gilliland, 2002). One approach for finding shared can-
cer stem cell markers is to focus on conserved stem and
progenitor cell functions. These functional markers may
be inherited by the malignant stem cell compartment
across multiple histological subtypes of cancer from the
same tissue of origin. A candidate marker which fits this
description is aldehyde dehydrogenase 1 (ALDH1), a de-
toxifying enzyme responsible for the oxidation of intracel-
lular aldehydes (Duester, 2000; Magni et al., 1996; Sophostem Cell 1, 555–567, November 2007 ª2007 Elsevier Inc. 555
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a role in early differentiation of stem cells through its role in
oxidizing retinol to retinoic acid (Chute et al., 2006). It has
been shown that murine and human hematopoietic and
neural stem and progenitor cells have high ALDH activity
(Armstrong et al., 2004; Hess et al., 2004, 2006; Matsui
et al., 2004). Increased ALDH activity has also been found
in stem cell populations in multiple myeloma and acute
myeloid leukemia (AML) (Matsui et al., 2004; Pearce
et al., 2005). ALDH activity may thus provide a common
marker for both normal and malignant stem and progeni-
tor cells.
In the present study, we demonstrate that cells with
ALDH activity isolated from normal human breast have
phenotypic and functional characteristics of mammary
stem cells. Moreover, the ALDEFLUOR-positive cells iso-
lated from human breast tumors contain the cancer stem
cell population. We also demonstrate that both normal
and malignant human mammary stem cells may be iden-
tified in situ using immunostaining. Analyzing the expres-
sion of ALDH1 in 577 human breast carcinomas from
two patient populations, we show that the expression of
this stem/progenitor cell marker is a powerful predictor
of poor clinical outcome. These findings provide support
for the ‘‘cancer stem cell hypothesis’’ and open new
possibilities for the study of mammary stem/progenitor
cells and their role in mammary development and carcino-
genesis. In addition, ALDH1 immunodetection is a sim-
ple method for identifying cancer stem/progenitor cells
in situ, facilitating the clinical application of stem cell
concepts.
RESULTS
The ALDEFLUOR-Positive Population Isolated
from Normal Mammary Epithelium
Has Stem Cell Properties
Single cell suspensions of normal mammary epithelial
cells were obtained by mechanical and enzymatic diges-
tion of breast reduction samples, as previously described
(Stingl et al., 1998; see the Supplemental Experimental
Procedures in the Supplemental Data available with this
article online). We utilized the ALDEFLUOR assay to as-
sess the presence and size of the population with ALDH
enzymatic activity in normal human breast epithelium.
Analysis of breast reduction samples from 14 different
patients showed an average of 8% (8.18 ± 4.31, n = 14)
ALDEFLUOR-positive population in normal mammary
epithelial cells (Figures 1A and 1B).
Using previously established in vitro and in vivo assays
(Dontu et al., 2003; Kuperwasser et al., 2004; Stingl et al.,
2006), we showed that functional characteristics as-
sociated with adult stem cells are displayed by the
ALDEFLUOR-positive, but not the ALDEFLUOR-negative,
population.
The ALDEFLUOR-positive population (Figures 1C–1E),
but not the ALDEFLUOR-negative population (Figures
1D and 1E), isolated from fresh mammoplasty samples
was capable of generating mammospheres in suspension556 Cell Stem Cell 1, 555–567, November 2007 ª2007 Elsevierculture at a density of 5000 cells/ml with a frequency of
approximately 4% (Figure 1E), in three consecutive pas-
sages. Similar results were obtained when cells were
plated in 96-well plates, 1 cell/well. The ALDEFLUOR-
positive cells generated mammospheres with an effi-
ciency of 10 ± 3.5%, whereas the ALDEFLUOR-negative
cells generated no spheres, and the unseparated cells
generated spheres with an efficiency of 0.5 ± 0.2%. The
difference between the low density culture and single
cell/well culture may be due to a degree of cell aggrega-
tion occurring in the former. These results are consistent
with our previous findings showing that mammary epi-
thelial cells that survive and proliferate in anchorage-
independent conditions are likely to be breast stem cells
with self-renewal capacity (Dontu et al., 2003). Similar
results were reported by studies in different tissues
(Li et al., 2003). ALDEFLUOR-positive cells sorted from
dissociated mammospheres were capable of self-renewal
in vitro, as shown by similar mammosphere-initiating
capacity in multiple passages (Figure 1E). The cell line-
age composition of the mammospheres was conserved
upon serial passages. ALDEFLUOR-positive cells were
enriched 10-fold in clonogenicity in suspension compared
to unseparated cells.
In a clonogenic assay that assesses the lineage differ-
entiation potential of single cells, the ALDEFLUOR-
positive cells were enriched in bilineage progenitor cells
that generated mixed ESA+/CD10+ colonies (Figure 1F–
1I). Figure 1I shows the numbers of myoepithelial, lumi-
nal epithelial, and mixed lineage colonies generated by
ALDEFLUOR-positive and ALDEFLUOR-negative cells.
The mixed lineage colonies represented 67.2 ± 3.5% of
the total number of colonies generated by ALDEFLUOR-
positive cells (237 ± 15 mixed colonies/1000 cells plated),
whereas they represented only 9.1 ± 1.3% of the colonies
generated by ALDEFLUOR-negative cells (7 ± 2 colonies/
1000 cells plated) (Figure 1I).
Differentiation potential of ALDEFLUOR-positive and
-negative populations was also assessed by flow cytome-
try analysis of lineage-specific markers expressed in the
progeny of these cells generated in cultivation conditions
that promote differentiation. Previous studies by Stingl
et al. showed that in the human mammary epithelium un-
committed progenitors double negative for CD10 and ESA
generate double negative progenitors bearing both
markers. Subsequently, these give rise to the single posi-
tive, lineage-committed progenitors. (Stingl et al., 1998).
Our results showed that, consistent with the findings of
the clonogenic assay, the ALDEFLUOR-positive popula-
tion was enriched in progenitors cells, which generated
uncommitted progeny (15.3 ± 3.2%, CD10/ESA;
21.2 ± 1.5%, CD10+/ESA+), myoepithelial (2.1 ± 0.3%,
CD10+/ESA), and luminal epithelial cells (63.2 ± 4.1%,
CD10/ESA+) (Figure 1J, left panel). The ALDEFLUOR-
negative population was highly enriched in progenitors
restricted to the luminal epithelial cell fate (93.5 ± 3.4%,
CD10/ESA+) (Figure 1J, right panel).
We utilized the mouse model described by Kuper-
wasser et al. to evaluate the ability of sorted cells fromInc.
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ALDH1 in Human Breast Stem CellsFigure 1. ALDEFLUOR-Positive Cells from Normal Breast Epithelium Have Stem Cell Properties
(A and B) Representative FACS analysis of normal breast epithelial cells using the ALDEFLUOR assay. Cells incubated with ALDEFLUOR substrate
(BAAA) and the specific inhibitor of ALDH, DEAB, were used to establish the baseline fluorescence of these cells (R1) and to define the ALDEFLUOR-
positive region (R2) (A). Incubation of cells with ALDEFLUOR substrate in the absence of DEAB induces a shift in BAAA fluorescence defining the
ALDEFLUOR-positive population (B). In all experiments, cells were first gated on PI negative cells (viable cells) which represented 93.4 ± 2.4%
(Mean ± SD, n = 31) of the total population.
(C–E) ALDEFLUOR-positive cells sorted from fresh reduction mammoplasties were enriched in sphere initiating cells (C) with 451 ± 42 mammo-
spheres (Mean ± SD, n = 6, derived from 3 different patients) generated by 10,000 cells plated versus 50 ± 8 mammospheres (Mean ± SD, n = 6)
generated by 10,000 unseparated cells (E). ALDEFLUOR-negative cells failed to grow in suspension (D and E). ALDEFLUOR-positive cells and
unseparated cells were capable of self-renewal in vitro, as shown by similar mammosphere-initiating capacity in three passages (E).
(F–J) Evaluation of the differentiation potential of ALDEFLUOR-positive and ALDEFLUOR-negative cells. Sorted cells were grown in differentiating
conditions for 12 days and stained by IHC with lineage-specific markers (ESA, CD10). The ALDEFLUOR-positive population generated 237 ± 15
mixed colonies/1000 cells plated (67.2 ± 3.5% bilineage colonies) (ESA+ cells stained in brown and CD10+ stained in purple) (F), 11 ± 1 myoepithelial
colonies/1000 cells plated (2.9 ± 0.5%) (CD10+) (G), and 108 ± 25 luminal colonies/1000 cells plated (30.6 ± 5.4%) (ESA+) (H). The ALDEFLUOR-
negative population produced 72 ± 10 luminal colonies/1000 cells plated (90.8 ± 3.1%) (ESA+) (H), and only 7 ± 2 mixed colonies/1000 cells plated
(9.1 ± 1.3%) (I). Data represent means ± SD, n = 6, derived from 3 different patients. ALDEFLUOR-positive and ALDEFLUOR-negative cells grown in
differentiating conditions were collected for flow cytometry analysis of lineage markers (ESA, CD10). ALDEFLUOR-positive cells generated uncom-
mitted progeny (15.3 ± 3.2%, CD10/ESA; 21.2 ± 1.5%, CD10+/ESA+), luminal cells (63.2 ± 4.1%, CD10/ESA+), and myoepithelial cells (2.1 ±
0.3%, CD10+/ESA), whereas ALDEFLUOR-negative cells generated predominantly luminal cells (93.5 ± 3.4%, CD10/ESA+) (J). Data represent
means ± SD, n = 3.normal breast epithelium to grow and differentiate in vivo
(Kuperwasser et al., 2004). ALDEFLUOR-positive,
ALDEFLUOR-negative, and unseparated cells were trans-
planted into humanized cleared mammary fat pads of
NOD/scid mice (25,000, 5,000, and 500 ALDEFLUOR-
positive cells; 50,000, 5,000 and 500 ALDEFLUOR-
negative cells; and 25,000, 5,000, and 500 unseparated
cells) (Figure 2A). Experiments were performed in tripli-
cate. All the cell subpopulations, including the unsepa-Cellrated cells, were stained with propidium iodide (PI) for
viability and sorted by side and forward scatter and viabil-
ity using flow cytometry (Figure S5). Only ALDEFLUOR-
positive and unseparated cells had outgrowth potential,
as shown by duct formation upon implantation of 25,000
cells (Figures 2B–2J). Moreover, the ALDEFLUOR-positive
cell population was considerably enriched in in vivo out-
growth capability because it consistently generated
10-fold more ducts in the humanized area of the mammaryStem Cell 1, 555–567, November 2007 ª2007 Elsevier Inc. 557
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ALDH1 in Human Breast Stem CellsFigure 2. In Vivo Outgrowth Potential of Normal Human Breast Epithelial Cells Sorted by the ALDEFLUOR Assay
(A) Table showing the number of outgrowths generated in NOD/scid mouse fat pads by ALDEFLUOR-positive, ALDEFLUOR-negative, and unsep-
arated cells.
(B–J) Hematoxylin and eosin staining of ducts generated by ALDEEFLUOR-positive cells (B, E, and H), ALDEFLUOR-negative cells (C, F, and I), and
unseparated cells (D, G, and J). The number of cells injected is indicated on the left side (25,000 cells in [B]–[D], 5,000 cells in [E]–[G], and 500 cells in
[H]–[J]). We observed formation of ducts in the fat pads injected with 25,000 and 5,000 ALDEFLUOR-positive (B and E) or unseparated cells (D and G).
Only residual Matrigel and mouse tissue were observed in all the other fat pads (C, F, and H–J).
(K and L) Evaluation of the number of ducts generated by each population (ALDEFLUOR-positive, ALDEFLUOR-negative, and unseparated). Only the
ALDEFLUOR-positive and unseparated cells produced outgrowths. The ALDEFLUOR-positive cells produced significantly more ducts than the
unseparated cells (p < 0.05).fat pad, compared to the unseparated population (Fig-
ures 2K–2L). The ALDEFLUOR-negative population
failed to repopulate the fat pads, even when 50,000
cells were injected (data not shown). We validated
the human origin of the epithelial outgrowths by immu-
nostaing with a human-specific antibody anti-ESA (Fig-
ures 3A–3D). As is the case in the human mammary
tree, these small ducts generated in the animal host
were composed of a luminal epithelial layer, expressing
CK18, and an outer myoepithelial cell layer, expressing
smooth muscle actin (SMA) (Figure 3E). This outer layer
was not generated by myofibroblastic conversion be-
cause it stained double-positive for CK14 and SMA
(Figure 3I). We also documented the cell lineage evolu-
tion by showing the presence of progenitor cells iden-
tified by double-positive staining with luminal and basal
markers, such as CK14/CK18, CK18/CK17, and CK18/
CK5/6 (Figures 3F–3H) (Villadsen et al., 2007).
Taken together, the results of the in vivo and in vitro
assays indicate that the ALDEFLUOR-positive cells repre-558 Cell Stem Cell 1, 555–567, November 2007 ª2007 Elseviersent the cell population with the broadest differentiation
potential in vitro and highest growth potential in vivo.
In Situ Characterization of ALDH1-Positive
Cells in Normal Breast Epithelium
and Mammosphere Sections
We next investigated whether ALDH1 immunohistochem-
istry (IHC) could be used to detect mammary stem/pro-
genitor cells in situ. We utilized flow cytometry analysis
to determine the overlap between the cell population
with a high ALDH enzymatic activity (ALDEFLUOR-
positive) and the population immunostained by ALDH1.
The ALDEFLUOR-positive and -negative populations
from normal breast epithelium were isolated by FACS,
fixed, and stained with an ALDH1 monoclonal antibody.
The cells detected by immunostaining were all contained
in the ALDEFLUOR-positive population, whereas the
ALDEFLUOR-negative population contained no ALDH1-
positive cells (Figures S1A–S1C). We confirmed the
results of this analysis by immunostaining separatedInc.
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ALDH1 in Human Breast Stem CellsFigure 3. Characterization of the Duct Outgrowths Generated in Humanized NOD/scid Cleared Fat Pads by ALDEFLUOR-Positive
Cells from Normal Breast Epithelium
(A–D) Evidence of the human origin of the epithelial ducts. Positive staining with a specific human antibody (anti-ESA) (A and B) which does not cross-
react with mouse tissue (C and D) confirms the human origin of the ductal structure (red staining).
(E–I) Cell composition of ducts generated by ALDEFLUOR-positive cells. The ducts had a luminal layer (stained with anti-CK18, green signal) and
a myoepithelial layer (stained with SMA, red signal). Double staining with luminal-like cytokeratin (CK18; green signal) and basal-like cytokeratins
(CK14, CK17, CK5/6, red signal) (E) demonstrated a partial overlap between the luminal cells and the basal cells (yellow signal in the composite image,
merge) suggesting a lineage evolution during duct formation (F–H). Double staining with CK14 (green signal) and SMA (red signal) showed cells pos-
itive for both markers (yellow signal) on the composite image (merge) (I). All nuclei were counterstained with DAPI.ALDEFLUOR-positive and -negative cells on cytospins
(Figures S1D and S1E).
Immunostaining of paraffin-embedded sections of
normal breast epithelium using the ALDH1 antibody iden-
tified a relatively rare population of ALDH1-positive cells
located in the terminal ductal lobular units (TDLUs).
ALDH1-positive cells appeared to form a bridge in the lu-
men that could be located at the bifurcation point of side
branches in the TDLUs (Figures 4A–4C; Figure S2). This
is consistent with recent published data that show that hu-
man stem/progenitor cells are localized in the ductal part
of the TDLU structures (Villadsen et al., 2007). A stem cell
marker would not be expected to colocalize with markers
of mature differentiated mammary epithelial cells. We per-
formed double staining with ALDH1 and CK18, a marker of
luminal epithelial cells and ALDH1 and SMA, a marker of
myoepithelial cells. The ALDH1-positive cells did not co-
localize with CK18 or SMA in sections through normal
human breast epithelium (Figures 4E and 4F). Although
the phenotype of normal stem and/or progenitor cells
from the human breast epithelium has not been identified,
several markers including CK5/6 and CK14 have beenCell Sfound to be associated within undifferentiated mammary
epithelial cells (Boecker et al., 2002; Gudjonsson et al.,
2002). We did not detect overlapping expression between
CK5/6 or CK14 and ALDH1 in sections through normal
human breast epithelium (data not shown). To determine
if this was a result of the scarcity of these populations,
we repeated the same analysis on mammosphere sec-
tions. We have shown previously that mammospheres
generated from normal mammary epithelium are enriched
in stem/progenitor cells (Dontu et al., 2003). The ALDH1-
positive cells represented approx 5% of the mammo-
sphere cell population (Figure 4D). A subset of these
ALDH1-positive cells expressed CK5/6 or CK14 (Figures
4G and 4H). These results are consistent with the hypoth-
esis that ALDH1-positive cells represent the stem/progen-
itor population of the normal human breast epithelium.
ALDEFLUOR-Positive Breast Carcinoma Cells
Display Properties of Cancer Stem Cells
To investigate the tumorigenicity of the ALDEFLUOR-
positive population in breast cancers, we established
xenotransplants from four independent human breasttem Cell 1, 555–567, November 2007 ª2007 Elsevier Inc. 559
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ALDH1 in Human Breast Stem CellsFigure 4. Characterization of ALDH1-Positive Cells Present in the Normal Breast Epithelium and in Mammosphere Sections
(A–C) ALDH1 staining of normal breast epithelium. ALDH1-positive cells (red cytoplasmic staining) were in a luminal location, bridging across the
lumen, probably at branching points of side-ducts (arrows).
(D) ALDH1 staining in mammospheres. Only 1–5 cells/mammosphere showed positive staining for ALDH1, (approximately 5% of the total population).
(E and F) Immunofluorescence of normal breast epithelium. Double staining with CK18 (red) and ALDH1 (green). Composite image (merge) showed
absence of overlap between CK18 positive cells (mature luminal cells) and ALDH1-positive cells (arrow). (E) Double staining with SMA (green) and
ALDH1 (red). Composite image (merge) showed absence of overlap between SMA-positive cells (mature myoepithelial cells) and ALDH1-positive
cells (arrow) (F).
(G and H) Immunofluorescence of mammosphere sections. Double staining with CK5/6 (green) and ALDH1 (red). Composite image (merge) showed
that only few ALDH1-positive cells displayed an exclusive red signal (arrow), whereas all the CK5/6-positive cells (asterisk) displayed a hybrid signal
(yellow) corresponding to cells positive for ALDH1 and CK5/6 (G). Double staining with CK14 (green) and ALDH1 (red). Composite image (merge)
showed that most of the ALDH1-postive cells displayed an exclusive red signal (asterisk), whereas all the CK14 positive cells (arrow) displayed a hy-
brid signal (yellow) corresponding to cells positive for ALDH1 and CK14 (H). All nuclei were counterstained with DAPI.cancers (MC1, UM1, UM2, and UM3). Cells from these
tumors were transplanted orthotopically in the humanized
cleared fat-pad of NOD/scid mice, without cultivation
in vitro. The tumors were invasive ductal carcinomas,
three ER-PR-ERBB2- (MC1, UM1, and UM3) and one
ER+PR+ERBB2 (UM2). The tumorigenicity of the sorted
ALDEFLUOR populations was assessed in early passages
in animals. In contrast to assays that test tumorigenicity of
sorted populations directly from patient tumors, this ex-
perimental design minimizes the bias introduced by the
variable ability of breast cancers to xenotransplant. We
found that the ALDEFLUOR-positive population in these
three tumors represented 3% to 10% of the total cell
population (Figures 5A and 5B; Figure S3). We performed
serial passages in vivo, using limiting dilutions of
ALDEFLUOR-positive, -negative, and unseparated cells
(50,000 cells, 25,000 cells, 5,000 cells, and 500 cells).
Experiments were performed in triplicate. For each of
the four tumors and for each of the three passages per-
formed, only the ALDEFLUOR-positive population formed
tumors, even when implanted in low numbers (Table S1;
Figure S3). As shown in Figure 5D, the size and latency560 Cell Stem Cell 1, 555–567, November 2007 ª2007 Elsevierof tumor formation correlated with the number of
ALDEFLUOR-positive cells injected. Remarkably, 500
ALDEFLUOR-positive cells generated a tumor in as few
as 40 days. ALDEFLUOR-negative cells failed to reproduc-
ibly generate tumors, although limited growth was ob-
served when 50,000 ALDEFLUOR-negative cells were in-
jected. This is consistent with the presence of less than
0.01% contaminating ALDEFLUOR-positive cells, which
is within the limits of FACS error. Alternatively, the growth
may have been generated by progenitor cells with limited
proliferation capacity. This would explain why these
tumors could not be passaged more than once when im-
planted as unseparated cells in the mouse fat pad. H&E
staining of the fat-pad sections confirmed that tumors
formed by ALDEFLUOR-positive cells contained malig-
nant cells (Figure 5F), whereas only residual Matrigel,
apoptotic cells, and mouse tissue were seen at the sites
of the ALDEFLUOR-negative cell injections (Figure 5G).
No tumors were detected at these sites after 20–34 weeks.
Consistent with the ALDEFLUOR-positive population
having stem cell characteristics, tumors generated by
this population recapitulated the phenotypic heterogeneityInc.
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ALDH1 in Human Breast Stem CellsFigure 5. The ALDEFLUOR-Positive Cell Population from Human Breast Tumors Xenografted in NOD/scid Mice Has Cancer Stem
Cell Properties
(A and B) Representative flow cytometry analysis of ALDH activity in cells derived from a human breast tumor orthotopically xenotransplanted in NOD/
scid mice. The ALDEFLUOR assay was performed as described above. In addition, mice of cell origin were eliminated from the analysis (see Sup-
plemental Experimental Procedures and Figure S5). All the ALDEFLUOR analyses on human breast tumor cells were first gated on PI negative cells
(viable cells), which represented 73.6 ± 1.8% (Mean ± SD, n = 43) of the total population. (C–G) The ALDEFLUOR-positive population had cancer stem
cell properties. The ALDEFLUOR-positive population was capable of regenerating the phenotypic heterogeneity of the initial tumor after a passage in
NOD/scid mice. (C) Tumor growth curves were plotted for the numbers of cells injected (50,000 cells, 5,000 cells, and 500 cells) and for each pop-
ulation (ALDEFLUOR-positive, ALDEFLUOR-negative, unseparated). Tumor growth kinetics correlated with the latency and size of tumor formation
and the number of ALDEFLUOR-positive cells (D). (E–G) Representative tumor grown in NOD/scid mouse at the ALDEFLUOR-positive cells’ injection
site (5,000 cells injected). No tumor was detected at the ALDEFLUOR-negative cells’ injection site (5,000 cells injected). (E and G) H&E staining of
ALDEFLUOR-positive cells’ injection site, revealing presence of tumor cells (F). The ALDEFLUOR-negative cells’ injection site contained only residual
Matrigel, apoptotic cells, and mouse tissue (G). All the data presented in this figure were generated by analysis of the MC1 tumor. Similar results were
obtained for three other tumors, generated from different patients (UM1, UM2, and UM3) tested (Figure S4). Data represent mean ± SD.of the initial tumor with a similar ratio of ALDEFLUOR-
positive and negative cells (Figure 5C). This indicates
that the ALDEFLUOR-positive cells were able to self-
renew, generating ALDEFLUOR-positive cells, and were
able to differentiate, generating ALDEFLUOR-negative
cells. We investigated the overlap between the
ALDEFLUOR-positive population and the previously
described breast cancer stem cell phenotype, CD44+/
CD24/lin (Al-Hajj et al., 2003). Flow cytometry analysis
of the xenografted tumors showed that these two pheno-
types, ALDEFLUOR and CD44+/CD24/lin, identified
a small overlapping cell fraction, representing 1.2%,
0.1%, and 0.9% in MC1, UM1, and UM2, respectively
(Figures 6A and 6B; Figure S4). We tested tumorigenicity
of the cells defined by both phenotypes in the MC1 tumor.
The cell population bearing both cancer stem cell pheno-
types had high tumorigenic capacity and generated a tu-
mor from as few as 20 cells (Figure 6E). By contrast, the
ALDEFLUOR-negative cells bearing the CD44+/CD24/
lin phenotype was not tumorigenic, even when im-
planted in numbers of 50,000 cells/fat pad (Figure 6D),Cell Ssuggesting that this population may lack tumorigenic
cells. The fact that the unseparated cells from the same
tumor sample were tumorigenic when more than 500 cells
were implanted (Figure 6C) supports this conclusion. The
ALDEFLUOR-positive population that did not display the
CD44+/CD24/lin phenotype was capable of generat-
ing tumors when implanted in numbers higher than 1500
cells (Figure 6F). We cannot exclude the possibility that
these tumors are generated by contaminating highly
tumorigenic cells. However, ALDEFLUOR-negative cells
did not generate tumors even from 50,000 cells. In addi-
tion, the tumors generated by 500 cells from the unsepa-
rated tumor population could not be passaged more than
once. Taken together, these findings suggest that the
ALDEFLUOR-positive/lin/Non CD44+/CD24 may con-
tain progenitor cells with limited proliferation potential.
Analysis of ALDH1 Protein on Tissue Microarrays
and Correlation with Histoclinical Parameters
To assess the potential use of ALDH1 as a diagnostic and
prognostic marker in breast cancer, we analyzed itstem Cell 1, 555–567, November 2007 ª2007 Elsevier Inc. 561
Cell Stem Cell
ALDH1 in Human Breast Stem CellsFigure 6. Tumorigenicity of the Cells Bearing the Overlapping Phenotype ALDEFLUOR-Positive and CD44+/CD24/lin
Cells were immunostained with a CD24–PE antibody and antibodies for lineage markers labeled PE-Cy5 and were subsequently stained with ALDE-
FLUOR. Cells were first gated based on viability and linmarkers, which represented 12.3 ± 1.1% of the total population. Cells of mouse origin were
also eliminated from the analysis. The four cell subpopulations defined by the ALDEFLUOR and CD44+/CD24/lin phenotypes were separated by
FACS. (A and B) The percentages shown in the diagram show the representation of the cell subpopulations in the total tumor cell population and the
overlap between the ALDEFLUOR phenotype and the CD24/CD44+/lin phenotype. (C–F) Tumorigenicity of the cell populations defined by the
ALDEFLUOR and CD44/CD24+/lin phenotypes was tested using the xenotransplantation model described. Experiments were performed in trip-
licate. The unseparated cells generated tumors when implanted in numbers higher than 500 cells (C). The ALDEFLUOR-negative CD44+/CD24/lin
cells were not tumorigenic, even at 50,000 cells/fat pad (D). The ALDEFLUOR-positive/CD44+/CD24/in cells generated tumors from as few as 20
cells (E). The ALDEFLUOR-positive/lin/NonCD44+/CD24 cells generated tumors when implanted in numbers higher than 1500 cells (F). Data rep-
resent mean ± SD.expression by IHC in two independent sets of breast tu-
mors (U.M. set, I.P.C. set), on tissue microarrays (TMAs).
Among these two sets, 481 tumors were available for
ALDH1 staining (136 cases from the U.M. set and 345
cases from the I.P.C. set). In the U.M. set, 24 tumors
(19%) expressed ALDH1 and 122 tumors (81%) did not.
Similar results were obtained in the I.P.C. set with 102
cases (30%) positive for ALDH1 staining and 243 cases
negative (70%) (Figures 7A–7D). Consistent with the idea
that cancer stem cells constitute a minority of the tumor
population, ALDH1-positive cells represented an average
of 5% of cells in tumors expressing ALDH1. Only two of
the 481 tumors had ALDH1 staining in the vast majority
of the cell population (Figure 7A). We investigated whether
ALDH1 expression correlates with the histoclinical char-
acteristics of the breast cancers. We found similar results
in both sets (Table S2). ALDH1-positive tumors were
associated with high histological grade (p < 0.05; U.M.562 Cell Stem Cell 1, 555–567, November 2007 ª2007 Elsevierset, p < 0.001; I.P.C. set, Fisher’s exact test), ERBB2 over-
expression (p < 0.05; U.M. set, p < 0.001; I.P.C. set,
Fisher’s exact test), and absence of estrogen and proges-
terone receptor expression (p < 0.05; U.M. set, p < 0.0001;
I.P.C. set, Fisher’s exact test). No correlation was found
with age, tumor size, and lymph node metastasis. We
also found a correlation between expression of ALDH1
and that of the basal-like cytokeratins CK5/6 (p < 0.05)
and CK14 (p < 0.01) (Table S2).
ALDH1 Protein Expression and Clinical Outcome
Analysis of overall survival (OS) showed a strong associa-
tion of ALDH1-positive tumors with poor clinical outcome
for both populations (p = 0.0459; U.M. set, p = 0.000675;
I.P.C. set, log-rank test) (Figures 7E and 7F). In the U.M.
set, the 5 year OS was 19.8% [14.52–97.28] for patients
with an ALDH1-positive tumor and 58.7% [33.22–100]
for patients with an ALDH1-negative tumor. In the I.P.C.Inc.
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(A–D) Example of ALDH1 staining in breast cancer. Only two of the 577 tumors analyzed were fully positive for ALDH1 (A). Representative examples of
breast tumor cores positive for ALDH1 with 5%–10% ALDH1-positive cells detected (B and C). Example of a tumor core with no detectable ALDH1
staining (D).
(E and F) Kaplan-Meier plot of patient overall survival: Survival differed significantly according to ALDH1 expression. Patients with tumors positive for
ALDH1 staining (green curve) had a poor prognosis compared to patients with tumors negative for ALDH1 staining (blue curve). Similar results were
observed in the U.M. set composed of 136 patients (p = 0.0459) (E) and I.P.C. set composed of 341 patients (p = 0.000675) (F).
(G) Cox multivariate analysis of overall survival for patients from I.P.C. set. When compared with known prognostic factors, ALDH1 status was an
independent factor of prognosis, as was Ki-67 status, tumor size, and SBR grade.set, the 5 year OS was 69.59% [60.73–79.73] for patients
with an ALDH1-positive tumor and 84.55% [80.02–89.33]
for patients with an ALDH1-negative tumor.
We performed a Cox multivariate analysis of OS in
which the values for ALDH1, tumor size, age, lymph
node metastasis, histological grade, ER, PR, Ki-67, and
ERBB2 were considered as categorical variables.
ALDH1 expression was an independent prognostic factor,
as was Ki-67 status, tumor size, and histological grade
(Figure 7G). The relative risk of death due to cancer was
1.76 for patients with ALDH1-positive tumors compared
to patients with ALDH1-negative tumors (p < 0.028).
DISCUSSION
The cancer stem cell hypothesis has fundamental implica-
tions for cancer biology in addition to clinical implications
for cancer risk assessment, early detection, prognostica-
tion, and prevention. The development of cancer thera-
peutics based on tumor regression may have produced
agents which kill differentiated tumor cells while sparing
the small cancer stem cell population (Wicha et al.,
2006). The development of more effective cancer thera-
pies may, thus, require targeting this important cancer
stem cell population. The success of these new ap-
proaches hinges on the identification, isolation, and char-
acterization of cancer stem cells. Recently, the phenotypeCell Sof the mouse mammary stem cells was identified by sev-
eral groups (Shackleton et al., 2006; Stingl et al., 2006).
These studies showed that an entire, functional mammary
gland can be regenerated in vivo in several serial pas-
sages, starting from a single cell (Shackleton et al.,
2006). Also, considerable progress has been made re-
cently toward identification of human mammary stem
cells, although the phenotype of these cells has remained
elusive (Clarke et al., 2006; Villadsen et al., 2007). Our
study indicates that ALDH1 is a marker of stem/progenitor
cells of the normal human breast and breast carcinomas.
Utilizing in vitro assays, we showed that ALDEFLUOR-
positive cells contain the subpopulation of normal breast
epithelium with the broadest lineage differentiation poten-
tial capable of self-renewal. These cells also have the
highest ability to grow in vivo in a xenotransplantation
animal model. In breast carcinomas, cells with high
ALDH activity contain the tumorigenic cell fraction able
to self-renew and to recapitulate the heterogeneity of the
parental tumor. With the caveat that xenotransplantation
may change the properties of normal and cancer cells,
this in vivo assay remains the gold standard for testing
functional stem cell properties. The ALDEFLUOR-positive
cell population has a small overlap with the previously de-
scribed cancer stem cell, CD44+/CD24/lin phenotype.
In the tumors we investigated, the overlap represented ap-
proximately 1% or less of the total cancer cell population.tem Cell 1, 555–567, November 2007 ª2007 Elsevier Inc. 563
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be highly enriched in tumorigenic capability, being able to
generate tumors from as few as 20 cells. It remains to be
determined if these phenotypes are associated with stem
cells in other breast cancers.
Identification of normal and malignant stem/progenitor
cells by the same marker supports the concept that
stem and progenitor cells are primary targets of transfor-
mation and, thus, lends further support to the cancer
stem cell hypothesis. In addition, the ability to identify
stem/progenitor cells by this shared phenotypic trait,
ALDH1 expression, permits analysis of cancer initiation
and progression from the normal to the premalignant
and then the malignant state. Unlike the previously de-
scribed breast cancer stem cell phenotype, which re-
quires the use of a combination of ten surface antigens
(Al-Hajj et al., 2003), testing for ALDH1 expression is a sim-
ple method for identifying normal and cancer stem cells,
amenable to clinical applications. We showed in the pres-
ent study that ALDH1 expression is a powerful prognostic
factor for breast cancer and it has direct or inverse corre-
lation with known histoclinical parameters, such as tumor
grade, ER/PR status, ERBB2 overexpression and basal-
like cytokeratins (CK 5/6 and CK14).
In the vast majority of breast tumors analyzed in this
study, the ALDH1-positive cells represented a relatively
small population, consistent with the notion that cancer
stem cells constitute a minority of the tumor population.
Remarkably, only two tumors out of 481 analyzed had
a predominant ALDH1-positive population. These tumors
had a very aggressive clinical evolution and may have
been driven by a stem cell population locked in self-
renewal, undergoing little or no differentiation.
We propose that ALDH1 expression in a subset of tu-
mors may reflect transformation of ALDH1-positive stem
or early progenitor cells in these tumors. By contrast,
ALDH1-negative tumors may be generated by the trans-
formation of ALDH1-negative progenitor cells. In the
ALDH1-positive tumors, the cancer stem cell population
may inherit properties of normal stem cells that confer
aggressiveness: ability to self-renew, high proliferation
potential, resistance to damaging agents, and chemore-
sistance. This hypothesis is consistent with studies in
AML (Bonnet et al., 1999). Alternatively, ALDH1-negative
tumors may contain rare ALDH1-positive cells below the
level of detection by immunostaining on TMAs. The detec-
tion of an ALDH1-positive population in TMA cores may be
due to an increased self-renewal activity in these tumors.
A recent study has shown that a gene expression signa-
ture associated with increased self-renewal of normal
stem cells is a predictor of poor prognosis (Glinsky et al.,
2005; Lahad et al., 2005). In agreement with our findings,
previously described molecular signatures of breast can-
cer associated with a poor prognosis for breast cancer
contain one or more ALDH isotypes (van’t Veer et al.,
2002). Recently, a combinatorial analysis of gene expres-
sion data was used to reanalyze the van’t Veer breast can-
cer gene expression data set (Alexe et al., 2006). This anal-
ysis identified 17 genes associated with poor prognosis in564 Cell Stem Cell 1, 555–567, November 2007 ª2007 Elsevierbreast cancer, two of which were ALDH isoforms. A recent
study showed that granulocyte macrophage progenitor
cells, transformed by the MLL-AF9 fusion protein, retained
the global expression profile of their normal cells of origin
and had only a subset of genes reprogrammed. This set
included 363 genes which were associated with self-re-
newal in normal hematopoietic stem cells including an
ALDH isoform (Krivtsov et al., 2006).
In conclusion, our study lends support to the cancer
stem cell hypothesis by showing that both normal and ma-
lignant mammary stem cells share a common functional
marker, ALDH1. Identification of ALDH1 as a potential
marker of normal and malignant human breast stem cells
opens important new avenues of research in normal
breast development and breast carcinogenesis. Further-
more, our study suggests that ALDH1 expression may
be used to detect both normal and malignant mammary
stem cells in situ, in fixed paraffin-embedded sections.
The clinical utility and relevance of this assay was demon-
strated by a strong association of ALDH1 expression with
clinical outcome in two independent tumor sets totaling
577 patients. Since ALDH is also expressed in hematopoi-
etic and neuronal stem cells, this marker may prove useful
for the detection and isolation of cancer stem cells in other
malignancies, thus facilitating the application of cancer
stem cell biology to clinical practice.
EXPERIMENTAL PROCEDURES
Dissociation of Normal Breast Epithelium
Normal breast tissue from reduction mammoplasties was dissociated
mechanically and enzymatically, as previously described (Stingl et al.,
1998; Supplemental Experimental Procedures) To generate single
cell suspension for the in vivo implantation, collagenase digestion
time was limited to 6 hr. The mammoplasty samples were procured
and utilized according to approved IRB protocols for research in
human subjects.
Mammosphere Culture
Mammosphere culture was performed as previously described (Dontu
et al., 2003). Single cells were plated in ultra-low attachment plates
(Corning, Acton, MA, USA) or plates coated with 1% agarose in
PBS, at a density of 20,000 viable cells/ml in primary culture and
5000 cells/ml in subsequent passages. In the 1 cell/well experiments,
conditioned medium from primary culture was used. Cells were plating
using a cell sorter during FACS. Ten plates were seeded from each of
the ALDEFLUOR-positive, -negative, and unseparated cell popula-
tions. For counting mammospheres, the content of all wells was
collected, pooled, and transferred on a collagen-coated dish in differ-
entiating medium (see below). Mammospheres adhered in these
conditions in approximately 48 hr, after which they were stained with
methyl blue and counted under low magnification.
Differentiating Culture Conditions
Single cell suspensions were plated on collagen-coated plates at
a density of 2000 viable cells/10 cm diameter dish. Cells were grown
in Ham’s F-12 medium (GIBCO INVITROGEN) with 5% fetal bovine
serum (FBS), 5 mg/ml insulin, 1 mg/ml hydrocortisone, 10 mg/ml cholera
toxin (Sigma, St Louis, MO, USA), 10 ng/ml epidermal growth factor
(BD Biosciences), and 13 Pen/Strep/Fungizone Mix (GIBCO). Cells
were fixed or collected for immunostaining after 12 days.Inc.
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Cells were stained fresh or after fixation in methanol or RNA- later (QIA-
GEN). Primary antibodies used were: ESA- FITC, CD10-PE (dilution
1:25, Novocastra, Newcastle, UK) and ALDH1 (dilution 1/100, BD
Biosciences). Incubation was performed for 20 min. on ice in Hanks
Balanced Salt Solution (HBSS, GIBCO) with 2% FBS, followed by
washing in HBSS with 2% FBS. The secondary antibody used was
anti-mouse labeled with phycoerythrin (PE) (dilution 1:250, Jackson
Labs, MA, USA). After incubation, cells were washed once with
HBSS and were resuspended in HBSS supplemented with 5% FBS.
For CD44/CD24/Lin staining the previously described protocol was
followed (Al-Hajj et al., 2003; Supplemental Experimental Procedures).
Fresh cells were stained with 1 mg/ml PI (Sigma) for 5 min for viability.
Analysis was performed using a FACStarPLUS (Becton Dickinson,
Palo Alto, CA, USA) flow cytometer.
Samples Used for Xenotransplantation
Human breast tumors were obtained as biopsy cores or pieces of
tumors after surgery and implanted in humanized cleared fat pads of
NOD/scid mice for establishing xenotransplants. The success of xeno-
transplantationwasapproximately20%,similar topreviousreports inthe
literature. Four xenotransplants were used: an ERPRERBB2 tumor
at the 15th passage in animals (MC1), an ERPRERBB2 tumor at
the 3rd passage (UM1), an ER+PR+ERBB2 tumor at the 4th passage
(UM2), and an ERPRERBB2 tumor at the 2nd passage (UM3). Two
of the xenotransplants were generated from metastatic tumors (MC1,
pleural effusion and UM2, ovarian metastasis) and two from primary
tumors (UM1 and UM3).
ALDEFLUOR Assay and Separation of the ALDH-Positive
Population by FACS
The ALDEFLUOR kit (StemCell Technologies, Durham, NC, USA) was
used to isolate the population with a high ALDH enzymatic activity.
Cells obtained from freshly dissociated normal breast epithelium or
breast cancer xenografts were suspended in ALDEFLUOR assay
buffer containing ALDH substrate (BAAA, 1 mmol/l per 1 3 106 cells)
and incubated during 40 min at 37C. As negative control, for each
sample of cells an aliquot was treated with 50 mmol/l diethylaminoben-
zaldehyde (DEAB), a specific ALDH inhibitor. In order to eliminate cells
of mouse origin from the xenotransplanted tumors, we used staining
with an anti-H2Kd antibody (BD biosciences, 1/200, 20 min on ice)
followed by staining with a secondary antibody labeled with phycoer-
ythrin (PE) (Jackson labs, 1/250, 20 min on ice). The sorting gates were
established using as negative controls the cells stained with PI only, for
viability, the ALDEFLUOR-stained cells treated with DEAB and the
staining with secondary antibody alone (Figures S5 and S6).
Animal Model
NOD/scid mice were used to assess the in vivo stem cell properties of
the ALDEFLUOR-positive population, compared to the ALDEFLUOR-
negative population and the unseparated population, from the normal
breast epithelium and the four tumor xenografts. The animal model
was described by Kuperwasser et al. for xenotransplantation of normal
mammary epithelial cells (Kuperwasser et al., 2004). The fat pads were
cleared prepuberty and humanized by injecting a mixture of irradiated
and nonirradiated immortalized human fibroblasts (1:1 irradiated:non-
irradiated, 50,000 cells/100 ml Matrigel/fat pad). Irradiated fibroblasts
(4 Gy) support growth of normal and cancer epithelial cells by secreting
a variety of growth factors, collagen, and possibly directly interacting
with the epithelial cells (Orimo et al., 2005; Tlsty, 2001). The immortal-
ized fibroblasts were primary human mammary fibroblasts stably
transfected with a retrovirus construct expressing telomerase. The fi-
broblast cell line is a generous gift from Dr. John Stingl and Dr. Connie
Eaves (Terry Fox Laboratory, Vancouver, British Columbia, Canada).
Estrogen pellets were implanted subcutaneously at the time of the
clearing. The suspension of normal and malignant breast cells were
obtained using the same dissociation method described above (see
also Supplemental Experimental Procedures) with the exception ofCellcollagenase incubation time, which was 1 hr. Cells were mixed with
Matrigel (BD biosciences) (1:1) and implanted in the cleared human-
ized fat pads 2–4 weeks later. The animals injected with normal breast
cells were euthanized after 10 weeks. The animals injected with cancer
were euthanized when the tumors were approximately 1.2 cm in the
largest diameter to avoid tumor necrosis and to comply with regula-
tions for use of vertebrate animal in research. A portion of each fat
pad injected was fixed in formalin and embedded in paraffin for histo-
logical analysis. For the evaluation of the outgrowth potential of each
cell population, we analyzed thirty sections from each fat pad injected
with sorted cells. H&E staining was performed every ten serial sections
(4 slides/fat pad). For each H&E slide, the ductal structures present
were counted under the microscope and averaged. The animal studies
were approved by the ULAM committee for research in vertebrate
animals.
Tissue Microarrays
The TMAs were provided by the Tissue Microarray Core laboratory at
University of Michigan Medical School and by the Laboratoire d’Onco-
logie Moleculaire, Institut Paoli-Calmettes de Marseille. The first TMA
contained 154 breast cancer cores from a consecutive population of
patients treated at the University of Michigan Hospital, MI, USA
(U.M. set) between 1984 and 1991, and the second TMA contained
552 breast cancer cores from a consecutive population of patients
treated at the Institut Paoli-Calmettes, Marseille, France (I.P.C. set) be-
tween 1987 and 1999. Clinical and histopathological data are available
for these patients (Jacquemier et al., 2005; Kleer et al., 2003).
Immunostaining
To assess the lineage composition of the colonies, cells were fixed on
plates for 20 min in methanol at 20C and were then stained using
Peroxidase Histostain-Plus and Alkaline-phosphatase Histostain-
Plus kits (Zymed, South San Francisco, CA, USA), according to the
manufacturer’s protocol. The same fixation and staining protocol
was used for cytospins. The primary antibodies, ALDH1, cytokeratin
18, ESA, and CD10, were used at the dilutions indicated by the manu-
facturer. DAB (Zymed) and AEC were used as substrate for peroxidase
and NBT/BCIP (GIBCO) for alkaline phosphatase.
For ALDH1 and ESA immunostaining, the paraffin-embedded sec-
tions through mammospheres, normal breast tissue, and the TMAs
were deparaffinized in xylene and rehydrated in graded alcohol. Anti-
gen enhancement was done by incubating the sections in citrate buffer
pH6 (Dakocytomation, Copenhagen, Denmark) as recommended.
Staining was done using Peroxidase histostain-Plus Kit (Zymed)
according to the manufacturer’s protocol. ALDH1 antibody (BD biosci-
ences) was used at a 1/100 dilution and ESA antibody (Dakocytoma-
tion) was used at a 1/200 dilution. AEC (Zymed) was used as substrate
for peroxidase. Slides were counter-stained with hematoxylin and cov-
erslipped using glycerin. TMA results were expressed in terms of per-
centage (P) and intensity (I) of positive cells as described previously
(Ginestier et al., 2002). Results were scored by the quick score (Q)
(Q = P 3 I). For the TMA, the mean score of minimum 2 core biopsies
was calculated for each case.
For fluorescent double staining, the primary antibodies CK18, SMA,
CK 5/6, CK14, and CK17 (Novocastra) were used at the dilutions indi-
cated by the manufacturer. Texas-red and FITC labeled secondary an-
tibodies (Jackson Labs) were used at the dilution 1/250 and incubated
for 20 min. Nuclei were counterstained with DAPI/antifade (INVITRO-
GEN) and coverslipped. Sections were examined with a fluorescent
microscope (Leica, Bannockborn, IL, USA).
Statistical Analysis
Distributions of molecular markers and other categorical variables
were compared using standard chi2 tests or Fisher exact test. Statisti-
cal differences for the number of ductal structures were determined by
using one-way ANOVA for independent samples. The overall survival
interval was calculated from the date of diagnosis. For graphical pre-
sentation, follow-up was truncated at 100 months. Survival curvesStem Cell 1, 555–567, November 2007 ª2007 Elsevier Inc. 565
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pared by log-rank tests. The influence of ALDH1 expression status was
assessed in multivariate analysis by the Cox proportional hazard
models with a stepwise selection. The model was adjusted for usual
prognostic or predictive factors in breast cancer, including tumor
size, age, lymph node metastasis, histological grade, ER, PR, Ki-67,
and ERBB2 status. All statistical tests were 2-sided at the 5% level
of significance and were done using the R Version 2.3.0 software.
Survival rates and relative risks (RR) are presented with their 95%
confidence intervals (CI).
Supplemental Data
The Supplemental Data include six figures, two tables, and Supple-
mental Experimental Procedures and can be found with this article
online at http://www.cellstemcell.com/cgi/content/full/1/5/555/DC1/.
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